Evidence map›Paper›PMID 39462221›Full record

ArticleCancer science2025

Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study.

Chigusa Morizane, Makoto Ueno, Tatsuya Ioka, Masahiro Tajika, Masafumi Ikeda, Kensei Yamaguchi, Hiroki Hara, Hiroshi Yabusaki, Atsushi Miyamoto, Satoru Iwasa and 17 more

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Chigusa MorizaneNational Cancer Center Hospital, Tokyo, Japan.
Makoto UenoKanagawa Cancer Center, Yokohama, Japan.
Tatsuya IokaOncology Center, Yamaguchi University Hospital, Ube, Japan.
Masahiro TajikaAichi Cancer Center Hospital, Nagoya, Japan.
Masafumi IkedaNational Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-4050-2086
Kensei YamaguchiThe Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Hiroki HaraSaitama Cancer Center, Saitama, Japan.
Hiroshi YabusakiNiigata Cancer Center Hospital, Niigata, Japan.
Atsushi MiyamotoNational Hospital Organization Osaka National Hospital, Osaka, Japan.
Satoru IwasaNational Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3863-9582
Manabu MutoKyoto University Hospital, Kyoto, Japan.ORCID https://orcid.org/0000-0002-3127-8203
Tsutomu TakashimaGraduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Keiko MinashiChiba Cancer Center, Chiba, Japan.
Yoshito KomatsuHokkaido University Hospital, Sapporo, Japan.ORCID https://orcid.org/0000-0002-1570-6802
Tomohiro NishinaNational Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Takako Eguchi NakajimaSt. Marianna University School of Medicine, Kawasaki, Japan.
Atsuchi TakenoKansai Rosai Hospital, Amagasaki, Japan.
Toshikazu MoriwakiUniversity of Tsukuba Hospital, Tsukuba, Japan.
Masayuki FurukawaNational Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Takatoshi SaharaEisai Co., Ltd., Tokyo, Japan.
Hiroki IkezawaEisai Co., Ltd., Tokyo, Japan.
Maiko NomotoEisai Co., Ltd., Tokyo, Japan.
Shuya TakashimaEisai Co., Ltd., Tokyo, Japan.
Taisuke UeharaEisai Co., Ltd., Tokyo, Japan.
Setsuo FunasakaEisai Co., Ltd., Tokyo, Japan.
Masakazu YashiroGraduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.ORCID https://orcid.org/0000-0001-5743-7228
Junji FuruseKanagawa Cancer Center, Yokohama, Japan.

Funding

Eisai
6 · The paper itself

Abstract

Fibroblast growth factor receptors (FGFRs) are a highly conserved family of transmembrane receptor tyrosine kinases with multiple roles in the regulation of key cellular processes. Specific FGFR mutations have been observed in several types of cancers, including gastric carcinoma and cholangiocarcinoma. Dose escalation data of 24 Japanese patients with solid tumors treated with Tasurgratinib (previously known as E7090), a potent, selective FGFR1-3 inhibitor, was reported in a phase I, first-in-human, single-center study. Based on the safety, pharmacokinetic, and pharmacodynamic profiles observed in this study, the recommended dose of 140 mg once daily was selected for the expansion part (Part 2), a multicenter expansion of the dose-finding study restricted to patients with tumors harboring FGFR gene alterations. Safety and preliminary efficacy were assessed in Part 2. Pharmacodynamic pharmacogenomic markers (serum phosphate, FGF23, and 1,25-(OH)

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaStomach NeoplasmsAdultAgedFemaleFibroblast Growth Factor-23HumansMaleMiddle AgedProtein Kinase InhibitorsPyrimidinesReceptor, Fibroblast Growth Factor, Type 2Receptors, Fibroblast Growth FactorFGF23 protein, humanFibroblast Growth Factor-23Protein Kinase InhibitorsPyrimidinesReceptor, Fibroblast Growth Factor, Type 2Receptors, Fibroblast Growth FactorcholangiocarcinomaE7090FGFR2gastric cancerTasurgratinib

Identifiers

PMID39462221
PMCPMC11711049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.